Clinical Trial Update: Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer [Phase 2]

View source ↗

Summary

Phase II study of Axitinib (AG-013736) evaluating the VEGF pathway in metastatic, recurrent, or unresectable adrenocortical cancer has completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenal Cortex Neoplasms

Drugs mentioned

• INLYTA (AXITINIB)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adrenal Cortex Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2013-06-27